BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31726190)

  • 1. A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.
    Yauk CL; Harrill AH; Ellinger-Ziegelbauer H; van der Laan JW; Moggs J; Froetschl R; Sistare F; Pettit S
    Regul Toxicol Pharmacol; 2020 Feb; 110():104526. PubMed ID: 31726190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies.
    Corton JC; Mitchell CA; Auerbach S; Bushel P; Ellinger-Ziegelbauer H; Escobar PA; Froetschl R; Harrill AH; Johnson K; Klaunig JE; Pandiri AR; Podtelezhnikov AA; Rager JE; Tanis KQ; van der Laan JW; Vespa A; Yauk CL; Pettit SD; Sistare FD
    Toxicol Sci; 2022 Jun; 188(1):4-16. PubMed ID: 35404422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving forward in human cancer risk assessment.
    Paules RS; Aubrecht J; Corvi R; Garthoff B; Kleinjans JC
    Environ Health Perspect; 2011 Jun; 119(6):739-43. PubMed ID: 21147607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods.
    Waters MD; Jackson M; Lea I
    Mutat Res; 2010 Dec; 705(3):184-200. PubMed ID: 20399889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicogenomics - What added Value Do These Approaches Provide for Carcinogen Risk Assessment?
    Schmitz-Spanke S
    Environ Res; 2019 Jun; 173():157-164. PubMed ID: 30909101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity.
    Ellinger-Ziegelbauer H; Aubrecht J; Kleinjans JC; Ahr HJ
    Toxicol Lett; 2009 Apr; 186(1):36-44. PubMed ID: 18822359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of toxicogenomics and traditional approaches to inform mode of action and points of departure in human health risk assessment of benzo[a]pyrene in drinking water.
    Moffat I; Chepelev N; Labib S; Bourdon-Lacombe J; Kuo B; Buick JK; Lemieux F; Williams A; Halappanavar S; Malik A; Luijten M; Aubrecht J; Hyduke DR; Fornace AJ; Swartz CD; Recio L; Yauk CL
    Crit Rev Toxicol; 2015 Jan; 45(1):1-43. PubMed ID: 25605026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing chemical carcinogenicity: hazard identification, classification, and risk assessment. Insight from a Toxicology Forum state-of-the-science workshop.
    Felter SP; Bhat VS; Botham PA; Bussard DA; Casey W; Hayes AW; Hilton GM; Magurany KA; Sauer UG; Ohanian EV
    Crit Rev Toxicol; 2021 Sep; 51(8):653-694. PubMed ID: 35239444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing the 3Rs in regulatory toxicology - Carcinogenicity testing: Scope for harmonisation and advancing the 3Rs in regulated sectors of the European Union.
    Annys E; Billington R; Clayton R; Bremm KD; Graziano M; McKelvie J; Ragan I; Schwarz M; van der Laan JW; Wood C; Öberg M; Wester P; Woodward KN
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):234-42. PubMed ID: 24768934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities for an alternative integrating testing strategy for carcinogen hazard assessment?
    Doktorova TY; Pauwels M; Vinken M; Vanhaecke T; Rogiers V
    Crit Rev Toxicol; 2012 Feb; 42(2):91-106. PubMed ID: 22141324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of evidence from high-throughput screening and transcriptomic data in human health risk assessments.
    Mezencev R; Subramaniam R
    Toxicol Appl Pharmacol; 2019 Oct; 380():114706. PubMed ID: 31400414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating toxicogenomics into human health risk assessment: lessons learned from the benzo[a]pyrene case study.
    Chepelev NL; Moffat ID; Labib S; Bourdon-Lacombe J; Kuo B; Buick JK; Lemieux F; Malik AI; Halappanavar S; Williams A; Yauk CL
    Crit Rev Toxicol; 2015 Jan; 45(1):44-52. PubMed ID: 25605027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is current risk assessment of non-genotoxic carcinogens protective?
    Braakhuis HM; Slob W; Olthof ED; Wolterink G; Zwart EP; Gremmer ER; Rorije E; van Benthem J; Woutersen R; van der Laan JW; Luijten M
    Crit Rev Toxicol; 2018 Jul; 48(6):500-511. PubMed ID: 29745287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicogenomics applied to in vitro carcinogenicity testing with Balb/c 3T3 cells revealed a gene signature predictive of chemical carcinogens.
    Rohrbeck A; Salinas G; Maaser K; Linge J; Salovaara S; Corvi R; Borlak J
    Toxicol Sci; 2010 Nov; 118(1):31-41. PubMed ID: 20713471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.
    Bercu JP; Jolly RA; Flagella KM; Baker TK; Romero P; Stevens JL
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):369-81. PubMed ID: 20801182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving forward in carcinogenicity assessment: Report of an EURL ECVAM/ESTIV workshop.
    Corvi R; Madia F; Guyton KZ; Kasper P; Rudel R; Colacci A; Kleinjans J; Jennings P
    Toxicol In Vitro; 2017 Dec; 45(Pt 3):278-286. PubMed ID: 28911985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of toxicogenomics approaches for assessing the risk of nongenotoxic carcinogenicity in rat liver.
    Eichner J; Wrzodek C; Römer M; Ellinger-Ziegelbauer H; Zell A
    PLoS One; 2014; 9(5):e97678. PubMed ID: 24828355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of data across toxicity endpoints for improved safety assessment of chemicals: the example of carcinogenicity assessment.
    Madia F; Pillo G; Worth A; Corvi R; Prieto P
    Arch Toxicol; 2021 Jun; 95(6):1971-1993. PubMed ID: 33830278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.